Pub Date : 2026-01-09DOI: 10.1016/j.repc.2025.11.006
Shang Gechu, Wang Guan
{"title":"Integrating Natriuretic Peptide Screening in Diabetic Patients: Practical Insights from a Neurosurgical Perspective.","authors":"Shang Gechu, Wang Guan","doi":"10.1016/j.repc.2025.11.006","DOIUrl":"https://doi.org/10.1016/j.repc.2025.11.006","url":null,"abstract":"","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145953552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-09DOI: 10.1016/j.repc.2025.09.011
Hisato Takagi
{"title":"Right hemothorax due to a ruptured descending thoracic aortic aneurysm.","authors":"Hisato Takagi","doi":"10.1016/j.repc.2025.09.011","DOIUrl":"https://doi.org/10.1016/j.repc.2025.09.011","url":null,"abstract":"","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145953607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-09DOI: 10.1016/j.repc.2025.09.012
María Noelia Pizá, Lucía Fernández Gassó, Teresa López Fernández
{"title":"Late thrombosis of a left atrial appendage occlusion in a patient with cancer.","authors":"María Noelia Pizá, Lucía Fernández Gassó, Teresa López Fernández","doi":"10.1016/j.repc.2025.09.012","DOIUrl":"https://doi.org/10.1016/j.repc.2025.09.012","url":null,"abstract":"","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145953567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-09DOI: 10.1016/j.repc.2026.01.001
André M Leite-Moreira, Adelino F Leite Moreira
{"title":"From network pharmacology to preclinical trials: Embracing modern translational validation of traditional Chinese medicine.","authors":"André M Leite-Moreira, Adelino F Leite Moreira","doi":"10.1016/j.repc.2026.01.001","DOIUrl":"https://doi.org/10.1016/j.repc.2026.01.001","url":null,"abstract":"","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145953517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-09DOI: 10.1016/j.repc.2025.10.005
Chaoqun Xing, Haichen Guan, Xuemei Zhang, Xuanan Xiang, Zhiyong Yao
Introduction and objectives: Astragaloside IV (AS-IV) is an active compound that has demonstrated significant therapeutic potential for chronic heart failure (CHF), but its mechanism remains unclear. This study aimed to explore the regulatory mechanisms of AS-IV in the treatment of CHF.
Methods: The therapeutic targets and signaling pathways of AS-IV on CHF were predicted using network pharmacology. Molecular docking techniques were then used to validate these predicted results. Additionally, in vivo experiments were carried out for further validation, including echocardiographic studies, ELISA analysis, HWI measurements, HE staining, Hoechst staining, and western blotting analysis.
Results: Network pharmacology analysis showed that cell apoptosis and the PI3K-Akt signaling pathway may be the primary mechanisms for AS-IV in the treatment of CHF. Molecular docking has shown that AS-IV has a relatively high binding affinity to core targets. In vivo experiments have shown that AS-IV improves cardiac dysfunction caused by CHF, reduces biomarker levels, alleviates cardiac hypertrophy, attenuates myocardial pathological changes, inhibits myocardial apoptosis, and up-regulates the expression levels of P-PI3K and P-AKT proteins.
Conclusion: This study demonstrates that AS-IV delays the progression of CHF, which may be achieved by inhibiting myocardial apoptosis via activating the PI3K-AKT signaling pathway. These findings have laid the foundation for research and application of AS-IV in CHF treatment.
黄芪甲苷（Astragaloside IV, AS-IV）是一种治疗慢性心力衰竭（CHF）的活性化合物，但其作用机制尚不清楚。本研究旨在探讨AS-IV在CHF治疗中的调控机制。方法：应用网络药理学方法预测AS-IV对慢性心力衰竭的治疗靶点和信号通路。然后使用分子对接技术验证这些预测结果。此外，还进行了体内实验以进一步验证，包括超声心动图研究、ELISA分析、HWI测量、HE染色、Hoechst染色和western blotting分析。结果：网络药理学分析显示，细胞凋亡和PI3K-Akt信号通路可能是AS-IV治疗CHF的主要机制。分子对接表明AS-IV对核心靶点具有较高的结合亲和力。体内实验表明，AS-IV可改善CHF所致心功能障碍，降低生物标志物水平，减轻心肌肥厚，减轻心肌病理改变，抑制心肌凋亡，上调P-PI3K和P-AKT蛋白表达水平。结论：本研究表明，AS-IV可能通过激活PI3K-AKT信号通路抑制心肌凋亡，从而延缓CHF的进展。这些发现为AS-IV在CHF治疗中的研究和应用奠定了基础。
{"title":"Revealing the Regulatory Mechanism of Astragaloside IV in Treating Chronic Heart Failure through Network Pharmacology and Animal Experiments.","authors":"Chaoqun Xing, Haichen Guan, Xuemei Zhang, Xuanan Xiang, Zhiyong Yao","doi":"10.1016/j.repc.2025.10.005","DOIUrl":"https://doi.org/10.1016/j.repc.2025.10.005","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Astragaloside IV (AS-IV) is an active compound that has demonstrated significant therapeutic potential for chronic heart failure (CHF), but its mechanism remains unclear. This study aimed to explore the regulatory mechanisms of AS-IV in the treatment of CHF.</p><p><strong>Methods: </strong>The therapeutic targets and signaling pathways of AS-IV on CHF were predicted using network pharmacology. Molecular docking techniques were then used to validate these predicted results. Additionally, in vivo experiments were carried out for further validation, including echocardiographic studies, ELISA analysis, HWI measurements, HE staining, Hoechst staining, and western blotting analysis.</p><p><strong>Results: </strong>Network pharmacology analysis showed that cell apoptosis and the PI3K-Akt signaling pathway may be the primary mechanisms for AS-IV in the treatment of CHF. Molecular docking has shown that AS-IV has a relatively high binding affinity to core targets. In vivo experiments have shown that AS-IV improves cardiac dysfunction caused by CHF, reduces biomarker levels, alleviates cardiac hypertrophy, attenuates myocardial pathological changes, inhibits myocardial apoptosis, and up-regulates the expression levels of P-PI3K and P-AKT proteins.</p><p><strong>Conclusion: </strong>This study demonstrates that AS-IV delays the progression of CHF, which may be achieved by inhibiting myocardial apoptosis via activating the PI3K-AKT signaling pathway. These findings have laid the foundation for research and application of AS-IV in CHF treatment.</p>","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145953544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.repc.2025.06.008
Danish Hassan , Kashish Zehra Manjee , Tungki Pratama Umar , Mohammad Al Diab Al Azzawi , Salem Elshenawy , Wajeeh Ahmed Khan , Syed Rayyan Ahmed , Muhammad Sohaib Khan , Marium Amjad , Yasmine Adel Mohammed
Introduction and objectives
Patients with chronic obstructive pulmonary disease (COPD) undergoing coronary artery bypass grafting (CABG) face significant perioperative risks. The choice between off-pump and on-pump CABG techniques can impact clinical outcomes, particularly related to pulmonary function and postoperative recovery. This meta-analysis aims to evaluate the clinical efficacy and safety of off-pump versus on-pump CABG in patients with COPD.
Methods
A comprehensive search of medical databases including PubMed and Google Scholar was conducted to identify relevant studies comparing off-pump and on-pump CABG in COPD patients. The main outcomes included postoperative respiratory complications, mortality rates, length of hospital stay, and overall recovery. Results were pooled as relative risks (RR) or mean differences (MD) with 95% confidence intervals (CI).
Results
A total of seven studies (two randomized controlled trials (RCTs), one sub-study from a previous RCT, and four observational studies) comprising 1071 patients were included in the analysis. While postoperative respiratory complications were lower in the off-pump group, the difference was not statistically significant. However, off-pump CABG was significantly associated with reduced mortality (RR 0.21; 95% CI: [0.08, 0.54], p=0.001), shorter hospital stays (MD=−2.34; 95% CI: [−4.51, −0.17], p=0.03), reduced need for mechanical ventilatory support (MD=−4.73; 95% CI: [−6.17, −3.29], p<0.00001), and lower incidence of low cardiac output (RR=0.43, 95% CI [0.19, 0.99], p=0.05).
Conclusion
Off-pump CABG provides significant benefits over on-pump CABG in COPD patients by reducing mortality, hospital stay duration, the need for mechanical ventilatory support, and low cardiac output. The observed reduction in postoperative respiratory complications, although not statistically significant, may indicate potential clinical benefits of off-pump CABG. Further large-scale RCTs are needed to confirm these findings.
{"title":"Efficacy and safety of off-pump versus on-pump coronary artery bypass grafting in chronic obstructive pulmonary disease patients: A systematic review and meta-analysis","authors":"Danish Hassan , Kashish Zehra Manjee , Tungki Pratama Umar , Mohammad Al Diab Al Azzawi , Salem Elshenawy , Wajeeh Ahmed Khan , Syed Rayyan Ahmed , Muhammad Sohaib Khan , Marium Amjad , Yasmine Adel Mohammed","doi":"10.1016/j.repc.2025.06.008","DOIUrl":"10.1016/j.repc.2025.06.008","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Patients with chronic obstructive pulmonary disease (COPD) undergoing coronary artery bypass grafting (CABG) face significant perioperative risks. The choice between off-pump and on-pump CABG techniques can impact clinical outcomes, particularly related to pulmonary function and postoperative recovery. This meta-analysis aims to evaluate the clinical efficacy and safety of off-pump versus on-pump CABG in patients with COPD.</div></div><div><h3>Methods</h3><div>A comprehensive search of medical databases including PubMed and Google Scholar was conducted to identify relevant studies comparing off-pump and on-pump CABG in COPD patients. The main outcomes included postoperative respiratory complications, mortality rates, length of hospital stay, and overall recovery. Results were pooled as relative risks (RR) or mean differences (MD) with 95% confidence intervals (CI).</div></div><div><h3>Results</h3><div>A total of seven studies (two randomized controlled trials (RCTs), one sub-study from a previous RCT, and four observational studies) comprising 1071 patients were included in the analysis. While postoperative respiratory complications were lower in the off-pump group, the difference was not statistically significant. However, off-pump CABG was significantly associated with reduced mortality (RR 0.21; 95% CI: [0.08, 0.54], p=0.001), shorter hospital stays (MD=−2.34; 95% CI: [−4.51, −0.17], p=0.03), reduced need for mechanical ventilatory support (MD=−4.73; 95% CI: [−6.17, −3.29], p<0.00001), and lower incidence of low cardiac output (RR=0.43, 95% CI [0.19, 0.99], p=0.05).</div></div><div><h3>Conclusion</h3><div>Off-pump CABG provides significant benefits over on-pump CABG in COPD patients by reducing mortality, hospital stay duration, the need for mechanical ventilatory support, and low cardiac output. The observed reduction in postoperative respiratory complications, although not statistically significant, may indicate potential clinical benefits of off-pump CABG. Further large-scale RCTs are needed to confirm these findings.</div></div>","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":"45 1","pages":"Pages 25-36"},"PeriodicalIF":1.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145649888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.repc.2025.08.008
Pedro Santarém Semedo , Paulo Fonseca , Sílvia Ribeiro , Alexandra Castro , Pedro Marques , Daniel Bonhorst , Víctor Sanfins
Introduction and objectives
We present data from the national registry of implantable cardiac devices (CIED) promoted by the Portuguese Association of Pacing and Electrophysiology for the years 2021 and 2022.
Methods
This is an annual, voluntary, multicenter registry with retrospective data collection. The evolution of interventions over time and the distribution by type of device are evaluated.
Results
The overall trend has been one of growth in previous years and during the biennium, with an increase in the total number of interventions across all CIED types. The only exception was cardiac resynchronization therapy associated with defibrillation capacity, which saw a decrease from 2021 to 2022.
Conclusions
Following a period of stagnation in the years leading up to this report, possibly due to COVID-19, there was a significant increase in procedures in the years under review. This growth highlights the vitality of the sector in Portugal and its strong position within Europe. This registry allows for the monitoring of the situation of Portuguese centers in relation to CIED procedures and their evolution.
{"title":"Portuguese National Registry on cardiac implantable electronic devices (2021–2022)","authors":"Pedro Santarém Semedo , Paulo Fonseca , Sílvia Ribeiro , Alexandra Castro , Pedro Marques , Daniel Bonhorst , Víctor Sanfins","doi":"10.1016/j.repc.2025.08.008","DOIUrl":"10.1016/j.repc.2025.08.008","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>We present data from the national registry of implantable cardiac devices (CIED) promoted by the Portuguese Association of Pacing and Electrophysiology for the years 2021 and 2022.</div></div><div><h3>Methods</h3><div>This is an annual, voluntary, multicenter registry with retrospective data collection. The evolution of interventions over time and the distribution by type of device are evaluated.</div></div><div><h3>Results</h3><div>The overall trend has been one of growth in previous years and during the biennium, with an increase in the total number of interventions across all CIED types. The only exception was cardiac resynchronization therapy associated with defibrillation capacity, which saw a decrease from 2021 to 2022.</div></div><div><h3>Conclusions</h3><div>Following a period of stagnation in the years leading up to this report, possibly due to COVID-19, there was a significant increase in procedures in the years under review. This growth highlights the vitality of the sector in Portugal and its strong position within Europe. This registry allows for the monitoring of the situation of Portuguese centers in relation to CIED procedures and their evolution.</div></div>","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":"45 1","pages":"Pages 1-8"},"PeriodicalIF":1.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145649878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.repc.2025.08.007
Aurora Andrade , Sara Gonçalves , Ana Batista , Ana Teresa Timóteo , Ana Oliveira Soares , Fátima Franco , Otília Simões , Marisa Pardal , Mário Almeida , Margarida Lopes , Filipa Bernardo , José Silva-Cardoso
Introduction and objectives
Heart failure with reduced ejection fraction (HFrEF) poses a significant challenge to healthcare. While clinical trials have shown the therapeutic benefits of dapagliflozin in patients with HFrEF, it is essential to understand treatment patterns and patient characteristics in real-world settings. The EVOLUTION-HF study sought to address this gap by analyzing real-world data.
Methods
EVOLUTION-HF is a retrospective cohort study conducted at eight sites in Portugal, which included patients who began treatment with dapagliflozin for HFrEF. Medical records were reviewed to collect information on the initiation date of dapagliflozin (the index date) and at the six- and 12-month follow-ups.
Results
This study included 228 patients. The majority were male, with an average age of 65 years, a mean left ventricular ejection fraction of 29%, and 85% classified as NYHA class II. More prevalent comorbidities were dyslipidemia (59%) and arterial hypertension (56%). On the index date, baseline medications showed a high utilization of standard HFrEF therapies: 92% of patients received betablockers, 71% were on aldosterone antagonists, and 55% were taking angiotensin receptor-neprilysin inhibitors. At the end of the follow-up period, there was a significant increase in the dosage of beta-blockers and a decrease in the dosage of loop diuretics. A low discontinuation rate of 5% was observed for dapagliflozin.
Conclusions
These findings support the established safety profile of dapagliflozin. The patient characteristics in the EVOLUTION-HF study closely resemble those in the DAPA-HF randomized trial. The observed treatment patterns indicate an optimization in guideline-directed medical therapy.
{"title":"Real-world dapagliflozin treatment patterns in Portuguese patients with heart failure with reduced ejection fraction","authors":"Aurora Andrade , Sara Gonçalves , Ana Batista , Ana Teresa Timóteo , Ana Oliveira Soares , Fátima Franco , Otília Simões , Marisa Pardal , Mário Almeida , Margarida Lopes , Filipa Bernardo , José Silva-Cardoso","doi":"10.1016/j.repc.2025.08.007","DOIUrl":"10.1016/j.repc.2025.08.007","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Heart failure with reduced ejection fraction (HFrEF) poses a significant challenge to healthcare. While clinical trials have shown the therapeutic benefits of dapagliflozin in patients with HFrEF, it is essential to understand treatment patterns and patient characteristics in real-world settings. The EVOLUTION-HF study sought to address this gap by analyzing real-world data.</div></div><div><h3>Methods</h3><div>EVOLUTION-HF is a retrospective cohort study conducted at eight sites in Portugal, which included patients who began treatment with dapagliflozin for HFrEF. Medical records were reviewed to collect information on the initiation date of dapagliflozin (the index date) and at the six- and 12-month follow-ups.</div></div><div><h3>Results</h3><div>This study included 228 patients. The majority were male, with an average age of 65 years, a mean left ventricular ejection fraction of 29%, and 85% classified as NYHA class II. More prevalent comorbidities were dyslipidemia (59%) and arterial hypertension (56%). On the index date, baseline medications showed a high utilization of standard HFrEF therapies: 92% of patients received betablockers, 71% were on aldosterone antagonists, and 55% were taking angiotensin receptor-neprilysin inhibitors. At the end of the follow-up period, there was a significant increase in the dosage of beta-blockers and a decrease in the dosage of loop diuretics. A low discontinuation rate of 5% was observed for dapagliflozin.</div></div><div><h3>Conclusions</h3><div>These findings support the established safety profile of dapagliflozin. The patient characteristics in the EVOLUTION-HF study closely resemble those in the DAPA-HF randomized trial. The observed treatment patterns indicate an optimization in guideline-directed medical therapy.</div></div>","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":"45 1","pages":"Pages 13-21"},"PeriodicalIF":1.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145649872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.repc.2025.12.004
Vítor Paulo Martins
{"title":"The APAPE National Registry of Cardiac Implantable Devices – A Tool of Vitality and Progress for Portuguese Cardiology","authors":"Vítor Paulo Martins","doi":"10.1016/j.repc.2025.12.004","DOIUrl":"10.1016/j.repc.2025.12.004","url":null,"abstract":"","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":"45 1","pages":"Pages 10-12"},"PeriodicalIF":1.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145886209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.repc.2025.08.006
Lorena Herrador , Elena García Arumi , Fernando de Frutos
{"title":"Left ventricular cardiomyopathy due to CPT II hereditary deficiency. Keys to an infrequent diagnosis","authors":"Lorena Herrador , Elena García Arumi , Fernando de Frutos","doi":"10.1016/j.repc.2025.08.006","DOIUrl":"10.1016/j.repc.2025.08.006","url":null,"abstract":"","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":"45 1","pages":"Pages 37-40"},"PeriodicalIF":1.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145524583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号